Business
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced
About this update from Dyadic International, Inc.
[{"type":"text","content":"JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (\"bYoRNA\") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (\"mRNA\"). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health. “I am excited to announce this development and commercialization agreement to explore the potential to utilize our C1 protein production platform to produce high-quality messenger RNA products at lower cost which will be easier to manufacture than in vitro mRNA, making it accessible to everyone, including patients from poorer countries. The global mRNA vaccine and therapeutics market was valued at USD 34.7 billion in 2022 and is expected to reach USD 68.1 billion by 2030, making this an extremely valuable potential opportunity for both companies to enter the rapidly expanding market for mRNA-based vaccines and therapies, said Mark Emalfarb, Dyadic’s Chief Executive Officer. “If this collaboration is successful, Dyadic has the potential to receive certain defined milestone and royalty payments from bYoRNA and the ability to obtain a license to the BRNA platform,” Mr. Emalfarb concluded. “The COVID-19 pandemic brought mRNA technology to the forefront, showing its potential to prevent and treat diseases. Within this collaboration, we will combine our respective technologies to try to express \"bio\" RNA from Dyadic's eukaryotic C1-cells, to design, develop and commercialize messenger RNA products,” said Pascal Viguié, bYoRNA's Chief Executive Officer. “We believe that by combining bYoRNA’s novel eukaryotic \"bio\" RNA platform with Dyadic’s industrially proven C1 protein production platform, we will be able to provide the pharmaceutical industry with a more cost-efficient platform for manufacturing large quantities of lower cost mRNA, enabling access to mRNA va...